Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-02-07
2006-02-07
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S04400A, C514S046000, C514S231500, C514S356000, C536S023100, C536S027620, C536S027600, C536S022100, C536S027700, C536S120000, C435S006120, C546S296000, C544S242000, C544S296000, C544S277000
Reexamination Certificate
active
06995148
ABSTRACT:
The present invention relates to novel compounds that are novel adenosine receptor analogues. Specifically, the compounds of the present invention preferably function as both adenosine receptor agonists and ganglionic blocking agents. To achieve this functionality, the compounds of the present invention, preferably contain a ganglionic blocking motif, is inserted into the adenosine molecule. The ganglionic blocking motif preferably includes an elongated carbon chain that, in a particularly preferred embodiment, contains two terminal amino groups. The ganglionic blocking motif preferably includes a carbon along the elongated carbon chain that is integral to a cyclic ketal that is part of the adenosine molecule. In presently-preferred embodiments, the elongated carbon chain ranges from two to sixteen carbons in length. The compounds of the present invention will be useful for treatment of a variety of conditions including, but not limited to, hypertension, vasodilation, and ischemia.
REFERENCES:
patent: 4167565 (1979-09-01), Stein et al.
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 5861405 (1999-01-01), Jacobson et al.
patent: 5998388 (1999-12-01), Ellis et al.
patent: RE37045 (2001-02-01), Olsson et al.
patent: 6294522 (2001-09-01), Zablocki et al.
patent: 6376472 (2002-04-01), Myers et al.
patent: 6407076 (2002-06-01), Box et al.
Vidt, D.G.In: Goodfriend T.L. et al., Eds., Hypertensive primer, 2nded., (1999) p. 437-442.
Drury and Szent-Gyorgyi J. Phys. 1929 68:213-237.
Jacob, M.I. and Berne, R.M. Am. J. Phys. 1960; 198: 322.
Jacobson, K.A. et al. J. Medicinal Chem. 1992; 35:407-422.
Jacobson, K.A. et al. Mol. Pharm. 1985; 29: 126-133.
Bridges, A.J. et al. J. Medicinal Chem. 1988; 31:1282-1285.
Jarvis, M.F. et al. J. Pharm. Exp. Ther. 1989; 251: 888-893.
Fuetes, M. et al. J. Org. Chem. 1976; 41: 4074-4077.
Devasagayaraj, A. and Knochel, P. Tetrahedron Lett. 1995; 36: 8411-8414.
Klein, H. and Neff, H. Angewandte Chemie 1956; 68: 681-682.
Tamaru, X. et al. Angewandte Chemie, Int. Ed. English 1987; 26: 1157-1158.
Knoess, H.P. et al. J. Org. Chem., 1991; 56: 5974-5978.
Jackson Edwin K.
Jones Garth S.
Khare Devesh
Reed Smith LLP
University of Pittsburgh
Wilson James O.
LandOfFree
Adenosine cyclic ketals: novel adenosine analogues for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenosine cyclic ketals: novel adenosine analogues for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenosine cyclic ketals: novel adenosine analogues for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3662003